PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration…
The Pittsburgh Technology Council celebrated the 25th annual Tech 50 Awards on Nov. 10, 2021 to honor the fastest growing and most innovative technology companies, service providers and CEOS in the Pittsburgh region.
May 11, 2023CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncology
May 02, 2023EY Announces Teresa Whalen, RPh, CEO of CytoAgents as an Entrepreneur Of The Year® 2023 East Central Award Finalist
Ernst & Young LLP (EY US) today announced that Teresa Whalen, RPh, CEO of CytoAgents, was named an Entrepreneur Of The Year® 2023 East Central Award finalist.
January 01, 2023Our Region’s Business – CytoAgents
As Teresa Whalen says in her “Our Region’s Business” interview hosted by Bill Flanagan on WPXI-TV, “2023 will be a breakout year for CytoAgents.”
View all of the latest news and announcements from CytoAgents
Read what the media has to say about CytoAgents
Learn about past and upcoming events for CytoAgents